Study of visual acuity and intraocular pressure in the treatment of macular diabetic edema with intravitreous triamcinolone;Avaliação da acuidade visual e da pressão intraocular no tratamento do edema macular diabético com triancinolona intravítrea

Arquivos Brasileiros de Oftalmologia

Volumn 73, Issue 2, 2010, Pages 129-134

  Rezende, Marcussi Palata ^a   Dias, Alana Ferreira Gomes ^a   Oshima, Akiyoshi ^a,b   de Andrade, Eric Pinheiro ^a   Serracarbassa, Pedro Durães ^a,c  

^a HOSPITAL DO SERVIDOR PÚBLICO ESTADUAL DE SÃO PAULO   (Brazil)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Diabetic retinopathy; Intraocular pressure; Macular edema drug effects; Ocular hypertension; Triamcinolone acetonide therapeutic use; Visual acuity

Indexed keywords

ANTIINFLAMMATORY AGENT; TRIAMCINOLONE ACETONIDE;

AGED; ARTICLE; CASE CONTROL STUDY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC RETINOPATHY; DRUG EFFECT; FEMALE; FOLLOW UP; HUMAN; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; RETINA MACULA EDEMA; VISUAL ACUITY; VITREOUS BODY;

AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS; CASE-CONTROL STUDIES; DIABETIC RETINOPATHY; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTRAOCULAR PRESSURE; MACULAR EDEMA; MALE; MIDDLE AGED; TRIAMCINOLONE ACETONIDE; VISUAL ACUITY; VITREOUS BODY;

EID: 77955390110     PISSN: 00042749     EISSN: 16782925     Source Type: Journal    
DOI: 10.1590/S0004-27492010000200006     Document Type: Article

References (26)

1. Esteves J, Laranjeira AF, Roggia MF, Dalpizol M, Scocco C, Kramer CK, et al. Fatores de risco para retinopatia diabética. Arq Bras Endocrinol Metab. 2008;52(3):431-41.
2. Cogan DG, Toussaint D, Kuwabara T. Retinal vascular patterns. IV. Diabetic retinopathy. Arch Ophthalmol. 1961;66:366-78.
3. Chieh JJ, Roth DB, Liu M, Belmont J, Nelson M, Regillo C, et al. Intravitreal triamcinolone acetonide for diabetic macular edema. Retina. 2005;25(7):828-34.
4. th ed. St. Louis: Mosby; 2006. v.2, p.1241-323.
5. Khairallah M, Zeghidi H, Ladjimi A, Yahia SB, Attia S, Zaouali S, et al. Primary intravitreal triamcinolone acetonide for diabetic massive macular hard exsudates. Retina. 2005;25(7):835-9.
6. Photocoagulation for diabetic macular edema. Early Treatment of Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group. Arch Ophthalmol. 1985;103(12):1796-806.
7. Zein WM, Noureddin BN, Jurdi FA, Schakal A, Bashshur ZF. Panretinal photocoagulation and intravitreal triamcinolone acetonide for the management of proliferative diabetic retinopathy with macular edema. Retina. 2006;26(2): 137-42.
8. Lam DS, Chan Ck, Mohamed S, Lai TY, LI KK, Li PS, et al. A Prospective randomised trial of different doses of intravitreal triamcinolone for diabetic macular edema. Br J Ophthalmol. 2007;91(2):199-203.
9. Enaida H, Hata Y, Ueno A, Nakamura T, Hisatomi T, Miyazaki M, et al. Possible benefits of triamcinolone-assisted pars plana vitrectomy for retinal diseases. Retina. 2003;23(6):764-70.
10. Wilson CA, Berkowitz B, Sato Y, Ando N, Hand JT, de Juan E. Treatment with intravitreal steroid reduces blood-retinal barrier breakdown due to retinal photocoagulation. Arch Ophthalmol. 1992;110(8):1155-9.
11. Funatsu H, Yamashita H, Noma H, Mimura T, Yamashita T, Hori S. Increased levels of vascular endothelial growth factor and interleukin-6 in the aqueous humor of diabetics with macular edema. Am J Ophthalmol. 2002;133(1):70-7.
12. Nauck M, Karakiulakis G, Perruchoud AP, Papakonstantinou E, Roth M. Corticosteroids inhibit the expression of vascular endothelial growth factor gene in human vascular smooth muscle cells. Eur J Pharmacol. 1998;341(2-3):309-15.
13. Antcliff RJ, Spalton DJ, Stanford MR, Graham EM, Ffytche TJ, Marshall J. Intravitreal triamcinolone for uveitic cystoid macular edema: an optical coherence tomography study. Ophthalmology. 2001;108(4):765-72.
14. Martidis A, Duker JS, Greenberg PB, Rogers AH, Puliafito CA, Reichel E, et al. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology. 2002;109(5):920-7.
15. Moshfeghi DM, Kaiser PK, Scott I, Sears JE, Benz M, Sinesterra JP, et al. Acute endophthalmitis following intravitreal triamcinolone acetonide injection. Am J Ophthalmol. 2003;136(5):791-6. Comment in: Am J Ophthalmol. 2003;136(5):918-9. Am J Ophthalmol. 2004;137(6):1158-9; author reply 1160-1. Am J Ophthalmol. 2004;137(6):1159-60; author reply 1160-1. Am J Ophthalmol. 2004;137(6):1166; author reply 1167.
16. McCuen BW, Bessler M, Tano Y, Chandler D, Machemer R. The lack of toxicity of intravitreally administered triamcinolone acetonide. Am J Ophthalmol. 1981;91(6):785-8.
17. Jonas JB, Hayler JK, Panda-Jonas S. Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative vitreoretinopathy. Br J Ophthalmol. 2000;84(9):1064-7.
18. Kivilcim M, Peyman GA, El-Dessouky ES, Kazi AA, Cheema R, Hegazy H. Retinal toxicity of triamcinolone acetonide in silicone-filled eyes. Ophthalmic Surg Lasers. 2000;31(6):474-8.
19. Vasconcelos-Santos DV, Nehemy PG, Schachat AP, Nehemy MB. Secondary ocular hypertension after intravitreal injection of 4 mg of triamcinolone acetonide: incidence and risk factors. Retina. 2008;28(4):573-80.
20. Roth DB, Realini T, Feuer WJ, Radhakrishnan R, Gloth J, Heimmel MR, et al. Short-term complications of intravitreal injection of triamcinolone acetonide. Retina. 2008;28(1):66-70.
21. Rhee DJ, Peck RE, Belmont J, Martidis A, Liu M, Chang J, Fontanarosa J, et al. Intraocular pressure alterations following intravitreal triamcinolone acetonide. Br J Ophthalmol. 2006;90(8):999-1003.
22. Gillies MC, Sutter FK, Simposon JM, Larsson J, Ali H, Zhu M. Intravitreal triamcinolone for refractory diabetic macular edema: two year results of a double-masked, placebo-controlled, randomized clinical trial. Ophthalmology. 2006;113(9):1533-8.
23. Jonas JB, Kreissig I, Hugger P, Sauder G, Panda-Jonas S, Degenring R. Intravitreal triamcinolone acetonide for exsudative age related macular degeneration. Br J Ophthalmol. 2003;87(4):462-8.
24. Ozkiris A, Erkilic K. Complications of intravitreal injection of triamcinolone acetonide. Can J Ophthalmol. 2005;40(1):63-8.
25. Morlet N, Young SH. Prevention of intraocular pressure rise following intravitreal injection. Br J Ophthalmol. 1993;77(9):572-3.
26. Dwinger MC, Pieper-Bodeewes I, Eter N, Holz FG. [Variations in intraocular pressure (IOP) and necessity for paracentesis following intravitreal triamcinolone injection]. Klin Monatsbl Augenheilkd. 2005;222(8):638-42.